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OBJECTIVE — This multicenter study examined the impact of albumin excretion rate (AER)
onthecourseofestimatedglomerularﬁltrationrate(eGFR)andtheincidenceofsustainedeGFR
60 ml/min/1.73 m
2 in type 1 diabetes up to year 14 of the Epidemiology of Diabetes Inter-
ventions and Complications (EDIC) study (mean duration of 19 years in the Diabetes Control
and Complications Trial [DCCT]/EDIC).
RESEARCH DESIGN AND METHODS — Urinary albumin measurements from 4-h
urine collections were obtained from participants annually during the DCCT and every other
yearduringtheEDICstudy,andserumcreatininewasmeasuredannuallyinboththeDCCTand
EDIC study. GFR was estimated from serum creatinine using the abbreviated Modiﬁcation of
Diet in Renal Disease equation.
RESULTS — A total of 89 of 1,439 subjects developed an eGFR 60 ml/min/1.73 m
2 (stage
3 chronic kidney disease on two or more successive occasions (sustained) during the DCCT/
EDICstudy(cumulativeincidence11.4%).Ofthese,20(24%)hadAER30mg/24hatallprior
evaluations, 14 (16%) had developed microalbuminuria (AER 30–300 mg/24 h) before they
reachedstage3chronickidneydisease,and54(61%)hadmacroalbuminuria(AER300mg/24
h) before they reached stage 3 chronic kidney disease. Macroalbuminuria is associated with a
markedly increased rate of fall in eGFR (5.7%/year vs. 1.2%/year with AER 30 mg/24 h, P 
0.0001) and risk of eGFR 60 ml/min/1.73 m
2 (adjusted hazard ratio 15.3, P  0.0001),
whereas microalbuminuria had weaker and less consistent effects on eGFR.
CONCLUSIONS — Macroalbuminuria was a strong predictor of eGFR loss and risk of de-
velopingsustainedeGFR60ml/min/1.73m
2.However,screeningwithAERalonewouldhave
missed 24% of cases of sustained impaired eGFR.
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I
t has generally been thought that in-
creases in urine albumin excretion rate
(AER) precede a fall in glomerular ﬁl-
tration rate (GFR) in patients developing
diabetic chronic kidney disease (1). Some
large studies in patients with type 2 dia-
betes (2–4) and a few smaller studies in
individuals with type 1 diabetes (5–9),
however, have demonstrated that a sub-
stantialproportionofdiabeticindividuals
with decreased GFR levels do not have
increased AER.
In this article, we examine the effects
of prior and current levels of AER on the
rate of decline in estimated GFR (eGFR)
and on the risk of decreased levels of
eGFR (60 ml/min/1.73 m
2) in subjects
with type 1 diabetes in the Diabetes Con-
trol and Complications Trial (DCCT)
and/orthefollow-upEpidemiologyofDi-
abetes Interventions and Complications
(EDIC) study.
RESEARCH DESIGN AND
METHODS— The multicenter DCCT/
EDIC study started with 1,441 partici-
pants (10). Two participants were lost to
follow-upbeforedevelopingend-stagere-
nal disease (ESRD). Because neither AER
nor eGFR were measured during this pe-
riod,thesetwosubjectswerenotincluded
in the analyses herein. At DCCT baseline,
the remaining 1,439 participants had
normal GFR (serum creatinine 1.3
mg/dl and/or creatinine clearance 100
ml/min/1.73 m
2). At baseline, the AER
was40mg/24hfortheprimarypreven-
tion cohort and 200 mg/24 h for the
secondary intervention cohort.
Renal function and blood pressure
Urinewascollectedover4hyearlyduring
the DCCT and every other year in the
EDIC study (one-half of the cohort each
year) (10). Serum creatinine levels were
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EDIC study (10). The GFR was estimated
using the abbreviated Modiﬁcation of
Diet in Renal Disease formula (11). ACE
inhibitors were proscribed during the
DCCT (angiotensin II receptor blockers
[ARBs] were not yet available), and their
use was recorded only during the EDIC
study.
The DCCT/EDIC Central Biochemis-
try Laboratory measured serum creati-
nine using an automated kinetic
modiﬁcation of the Jaffe reaction on a
Beckman Synchron CX3 Clinical C Sys-
tem (12). Urine microalbumin was mea-
suredusingasolid-phasenoncompetitive
double-antibody ﬂuorescent immunoas-
say (13). The respective coefﬁcients of
variation were 2.3 and 9.4%, and the co-
efﬁcients of reliability for both were 94%
from masked split duplicate collections
originating at the study sites.
An abnormal eGFR was deﬁned as a
sustained value 60 ml/min/1.73 m
2 on
atleasttwosuccessivecollections.Parallel
analyses using a single eGFR 60 ml/
min/1.73 m
2 are presented in an on-
line appendix, available at http://care.
diabetesjournals.org/cgi/content/full/
dc09-1098/DC1. A value 60 ml/min/
1.73 m
2 (stage 3 chronic kidney disease)
has been used in other studies to indicate
signiﬁcant impairment of GFR (2–9).
ESRD was deﬁned as stage 5 chronic kid-
ney disease, which includes dialysis or
kidneytransplant.TheeGFRsforindivid-
uals who reached ESRD were imputed as
15 ml/min/1.73 m
2 thereafter in longitu-
dinal analyses.
AER was classiﬁed into three catego-
ries: no elevation, microalbuminuria
(30–300 mg/24 h), or macroalbuminuria
(300 mg/24 h) based either on the cur-
rent value at each visit or the history of
values up to a visit.
Statistical methods
Analyses used all AER and eGFR values
from the 1,439 participants over the 23
years of the DCCT/EDIC study. The
Kruskal-Wallis or Wilcoxon rank-sum
test for differences among groups was
used for quantitative or ordinal data and
the 
2 test for categorical data.
The general linear mixed model was
used to estimate the rate of change in log-
transformed eGFR during each of the
three AER states adjusted for medication
use and mean arterial pressure at the cur-
rentvisit,allastime-dependentcovariates
(14). This random coefﬁcient model used
the log of eGFR as the dependent variable
with a random time effect, an AER group
effect (normal, micro-, or macroalbumin-
uria), time by AER group interaction, and
other covariate effects. Information sand-
wich empirical variance estimates for the
ﬁxed effects were used to ensure valid in-
ferences, even if the covariance structure
was mis-speciﬁed (14). The model esti-
mated the change in log eGFR per year
(slope) for each subject while that subject
was in one or more of the three AER cat-
egories. The percent change in eGFR per
year was obtained as 100  [exp
(slope)  1], a negative value represent-
ingadecrease.Thedistributionofratesof
change in eGFR among subjects (the ran-
dom effects) were depicted using Kernel-
smoothed density estimates (15). The
model also provided estimates of the
mean level of eGFR over time for subjects
then in each category of AER.
The Cox proportional hazard model
assessed the effect of the AER state (cate-
gory) as a time-dependent covariate on
the risk of sustained abnormal eGFR60
ml/min/1.73 m
2 (16).
Additional models included interac-
tionsbetweenDCCTtreatmentgroup(in-
tensive versus conventional) and AER
categories to determine whether the same
relationships applied within each group.
RESULTS— Characteristics of the
1,439 participants at DCCT entry are
shown in Table 1; 156 (11%) had an AER
30 mg/24 h but 200 mg/24 h. During
the mean follow-up of 19 years in the
DCCT/EDIC study, 580 participants
(40%)developedmicroalbuminuriaonat
least one occasion and 164 (11%) devel-
oped macroalbuminuria on at least one
occasion. During the DCCT/EDIC study,
202participantsdevelopedaneGFR60
ml/min/1.73 m
2. Among the 178 subjects
with a subsequent visit, 108 had at least
one other eGFR 60 ml/min/1.73 m
2,
and 89 had sustained (two or more con-
secutive) eGFR levels 60 ml/min/1.73
m
2. Twenty of these 89 participants who
had macroalbuminuria when they devel-
oped sustained eGFR 60 ml/min/1.73
m
2 subsequently developed ESRD.
Figure 1A shows that the proportion
with normal AER up to the last visit
among those who never developed a sus-
tained eGFR 60 ml/min/1.73 m
2 was
greater than the proportion who had nor-
mal AER up to the time that an initial
eGFR 60 ml/min/1.73m
2 was ﬁrst ob-
served,asweretheproportionswithahis-
tory of microalbuminuria. Conversely,
the proportion of subjects with a history
of macroalbuminuria was markedly
higher among individuals with sustained
eGFR 60 ml/min/1.73 m
2 versus not.
Figure 1B shows that the cumulative
incidence of sustained eGFR 60 ml/
min/1.73 m
2 rose exponentially over the
23 years of observation from 1.1% at 10
years, to 7.3% at 20 years, and 11.4% at
23 years after the start of the DCCT.
Table 1 compares the characteristics
of individuals with no abnormal eGFR
versus those who developed sustained
eGFR 60 ml/min/1.73 m
2 according to
the history of prior albuminuria (none
versus micro- versus macroalbuminuria).
As would be expected, numerous differ-
ences were observed including lipids, use
of ACE inhibitors and ARB medications,
and history of hyperglycemia (A1C), but
not blood pressure or hypertension.
Table2presentstheCoxproportional
hazard model analyses of the risk of sus-
tained abnormal eGFR 60 ml/min/1.73
m
2asafunctionofhavingmicroalbumin-
uria or macroalbuminuria either at the
current visit at which an eGFR has been
measured (the current albuminuria
model) or at any visit up to the present
visit (the history of albuminuria model).
Inthecurrentalbuminuriamodel,among
individuals with normal AER at the cur-
rent visit, 30 experienced sustained eGFR
60 ml/min/1.73 m
2 corresponding to a
crude rate of 1.1 subjects per 1,000 pa-
tient-years. Among individuals with mi-
croalbuminuria at the current visit, the
rate was 4.4 per 1,000 patient-years. Ad-
justed for other factors, patients with mi-
croalbuminuria had a 3.3-fold increased
risk (hazard ratio) compared with pa-
tients with normal AER (P  0.0001).
Among individuals with current mac-
roalbuminuria, the rate was 46.7 per
1,000 patient-years, with an adjusted
15.3-fold increased risk (hazard ratio)
compared with individuals with normal
AER (P  0.0001).
A history of macroalbuminuria (pre-
viously or currently) was likewise associ-
ated with an 8.6-fold increased risk of
sustained abnormal eGFR over normal
AER, but the risk among patients with a
history of microalbuminuria was not dif-
ferent from patients with normal AER.
These risk ratios may be lower than those
using the current AER categories in part
because 90% of the 580 subjects with a
history of microalbuminuria reverted to
normal AER on at least one later visit.
Likewise, 19% of 164 subjects with a his-
tory of macroalbuminuria reverted to
normal AER, and 56% reverted to mi-
Molitch and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1537croalbuminuria transiently at some visit
later.
The general linear mixed model in
Table2alsoshowsthatwhilesubjectshad
normal AER, either currently or by his-
tory, the eGFR declined on average by
1.2% per year. However, the eGFR de-
clined by 1.8%/year while subjects cur-
rently had microalbuminuria, or 1.4%/
year with a history of microalbuminuria
(each P  0.0001 vs. normal AER). The
eGFR declined by 5.7% per year while
subjects currently had macroalbumin-
uria,or5.1%withahistoryofmacroalbu-
minuria, each signiﬁcantly higher than
with microalbuminuria, or with normal
AER (P  0.001).
Figure 2A presents the model-
estimated average decline in eGFR while
subjectscurrentlyhadnormalAERversus
microalbuminuria or macroalbuminuria.
Whereas the slopes in eGFR over visits
with normal AER and microalbuminuria
are signiﬁcantly different, the estimated
levelsofeGFRaresimilarovertimeowing
to slightly higher values early in the
DCCT for subjects with microalbumin-
uria. The subjects with macroalbumin-
uria had a much more rapid rate of
decline over time. A decline of 5.7% per
year over 10 years equates to 100  (1 
0.943
10)  44.4% decline. The analysis
based on a history of AER identiﬁes an
almost identical trend.
Figure 2B presents the smoothed dis-
tribution of the model-estimated patient-
speciﬁc percent change in eGFR per year
(slope)withineachcurrentAERcategory.
While subjects had normal AER or mi-
croalbuminuria, there was little variation
around the respective mean percent
change shown in Table 2 (i.e., a narrow
range from the highest to lowest values).
Conversely, while subjects had mac-
roalbuminuria, the distribution is ﬂat-
tened and skewed to the left with much
more variation among subjects, with
some subjects having as much as a 20%
reduction per year in eGFR.
Although the incidence of change in
eGFR or AER was signiﬁcantly higher in
the DCCT conventional than the inten-
sive treatment group, the relationships
between AER and eGFR described above
in the combined cohort applied to both
treatment groups. Tests of the interaction
between DCCT treatment group and AER
Table1—Characteristicsofthe1,439DCCT/EDICparticipantswithineachAERcategory(basedonthehistoryofAERvalues)atthelastvisit
for subjects with no sustained eGFR <60 ml/min/1.73 m
2 and at the initial abnormal eGFR visit for subjects with sustained eGFR <60
ml/min/1.73 m
2
Clinical characteristics
No sustained eGFR 60 ml/min/1.73 m
2
(n  1,350)
Sustained eGFR 60 ml/min/1.73 m
2
(n  89)
AER 30 AER 30–300 AER 300 Total Total AER 30 AER 30–300 AER 300
n 675 566 109 1,350 89 21 14 54
Primary cohort (%) 59 43 39* 50 52 67 79 39*
Intensive therapy (%) 54 50 28* 50 38† 57 43 30
Female (%) 43 53 34* 47 55 81 64 43*
DCCT baseline
Age (years) 28  72 6  72 5  7* 27  72 8  83 0  73 3  52 6  7*
Diabetes duration (years) 5.3  4.1 6.4  4.3 6.2  3.9* 5.8  4.2 5.8  3.8 4.0  3.0 4.3  3.8 6.9  3.8*
BMI (kg/m
2) 23  32 3  32 4  32 3  32 4  32 3  32 5  32 4  3
MAP (mmHg) 87  98 6  88 7  98 6  98 7  88 4  98 6  98 8  7
Hypertension (%)‡ 32 30 37 31 30 19 14 39
AER (mg/24 h) median (Q1, Q3)	 9 (6, 13) 14 (9, 27) 16 (9, 29)* 12 (7, 19) 12 (7, 19) 7 (4, 10) 12 (8, 19) 14 (7, 22)*
Clinical neuropathy (%)§ 6 6 11 6 10 5 7 13
HDL (mg/dl) 51  13 50  12 48  13* 51  12 50  13 55  14 50  13 49  13
LDL (mg/dl) 110  30 109  29 111  28 109  29114  26† 108  30 118  25 116  25
Triglyceride (mg/dl) 76  42 83  47 97  72* 80  48 94  44† 70  27 98  38 102  48*
eGFR (ml/min/1.73 m
2) 108  23 118  28 121  28* 113  26108  33† 85  20 94  23 121  33*
Diabetes duration at ﬁrst sustained 24.0 25.9 25.7 24.9 21.0 20.0 19.5 21.8
eGFR 60 ml/min/1.73 m
2 or last
GFR visit (years)  (5.7) (5.6) (5.0)* (5.7) (5.4) (5.6) (4.8) (5.4)
Take ACE inhibitors in EDIC study (%)¶ 44 53 81* 51 82† 43 93 94*
Take ARBs at EDIC year 13/14 (%)¶ 6.4 8.0 12.8 7.6 23.6† 14.0 21.4 27.8
DCCT mean A1C 7.8  1 8.3  1 9.4  1* 8.1  1 9.3  2† 7.8  1 8.9  2 10.0  1*
EDIC mean A1C up to year 13/14 7.7  1 8.2  1 8.9  1* 8.0  1 8.7  1† 7.7  1 8.7  1 9.1  1*
DCCT/EDIC follow-up (years) 19.0  4 19.6  3 19.8  3* 19.3  4 19.7  3 19.7  2 19.4  2 19.8  3
Data are means  SD for quantitative variables unless noted otherwise. No sustained eGFR includes subjects with all eGFR 60 ml/min/1.73 m
2 and subjects with
a history of single eGFR 60 ml/min/1.73 m
2, but no sustained eGFR 60 ml/min/1.73 m
2.* P  0.05 from a multiple-group comparison among the three AER
groups within the no sustained eGFR 60 ml/min/1.73 m
2 and sustained eGFR 60 ml/min/1.73 m
2 group, respectively, based ona2d fKruskal-Wallis test for
quantitative variables and a 
2 test for categorical variables. †P  0.05 from a between-group comparison between the no sustained eGFR 60 ml/min/1.73 m
2 and
sustained eGFR 60 ml/min/1.73 m
2 group as a whole, based on Wilcoxon rank-sum test for quantitative variables and a 
2 test for categorical variables.
‡Hypertension: systolic blood pressure 130 mmHg or diastolic blood pressure 80 mmHg. §Clinical neuropathy: a deﬁnite diagnosis of peripheral diabetic
neuropathy by clinical examination based on the presence of at least two of the following: physical symptoms, abnormalities on sensory examination, and absent or
decreased deep-tendon reﬂexes.  Diabetes duration up to the time of ﬁrst reported sustained eGFR 60 ml/min/1.73 m
2 or up to the last GFR visit for subjects with
nosustainedeGFR60ml/min/1.73m
2.NostatisticaltestwasconductedcomparingsubjectswithnosustainedeGFR60ml/min/1.73m
2versussustainedeGFR
60 ml/min/1.73 m
2 groups as a whole. ¶Use of ARBs was not collected before EDIC year 13/14. ACE inhibitor use was proscribed during the DCCT.
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1538 DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 care.diabetesjournals.orgFigure1—A:TheproportionsofsubjectswithahistoryofnormalAER(AER30mg/24h),microalbuminuria(AER30and300mg/24h),and
macroalbuminuria (AER 300 mg/24 h or ESRD) among subjects who never developed a sustained eGFR 60 ml/min/1.73 m
2 by the time of their
ﬁnal visit, or at the visit where a subject ﬁrst presents with a sustained eGFR 60 ml/min/1.73 m
2. B: Cumulative incidence of sustained eGFR 60
ml/min/1.73 m
2 during the DCCT/EDIC follow-up among the 1,439 DCCT/EDIC participants.
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tically signiﬁcant (adjusted for two tests
per model).
Additional analyses of a single eGFR
60 ml/min/1.73 m
2 showed a similar
but less signiﬁcant trend (see the online
appendix).
CONCLUSIONS — Itisgenerallybe-
lieved that microalbuminuria serves as a
marker for individuals who may develop
diabetic nephropathy and likely reﬂects
its earliest manifestation (1). However,
only 30–45% of individuals with mi-
croalbuminuria have been found to
progress to more advanced stages of
kidney disease in recent studies (17).
Furthermore, many patients with
microalbuminuria often revert to normal
AERs, as we have shown here and as has
been shown previously (18). Only part of
this reversion can be explained by good
glycemic control and/or use of antipro-
teinuric medications (18).
The assumption that patients ﬁrst pass
throughstateswithincreasinglevelsofAER
before eventually showing a decline in GFR
(1) has been challenged by several studies
whichshowedthatasubstantialproportion
of adults with type 2 diabetes developed
eGFR levels 60 ml/min 1.73m
2 had nor-
mal urinary AER (2–4).
Among DCCT/EDIC participants
with type 1 diabetes, only 34% of 202
participants who developed an eGFR
60 ml/min/1.73 m
2 had a history of
macroalbuminuria,with27%havingonly
microalbuminuria. To reduce the effects
ofrandomvariationsineGFRlevels,anal-
yses of 89 individuals who had sustained
eGFR 60 ml/min/1.73 m
2 showed that
61% had a history of macroalbuminuria
and 16% had microalbuminuria. Given
that some patients were taking ACE in-
hibitors and ARBs, classiﬁcation into
these categories must be considered to be
somewhat inexact. In a similar analysis of
71 subjects with type 1 diabetes who
had only single measurements of eGFR
60 ml/min/1.73 m
2, Costacou et al.
(8) found that 51 (72%) had prior mac-
roalbuminuria and 15 (21%) had prior
microalbuminuria.
A unique aspect of the DCCT/EDIC
study was the ability to determine the ef-
fects of antecedent levels of AER on the
risk and rate of progression to eGFR 60
ml/min/1.73 m
2. Using Cox proportional
hazards models, subjects having mi-
croalbuminuria currently present at the
time of the eGFR assessment had a 3.3-
fold increased risk of having an eGFR
60 ml/min/1.73 m
2 (sustained) at that
same visit compared with subjects with
normal AER at the time of the eGFR as-
sessment. The risk was increased 15.3-
Table 2—Progression of eGFR as a function of the category of AER in the DCCT/EDIC study (n  1,439) based on the current AER value or
the history of AER values
Models Effect
Number
with event
(n  89)†
Patient-
years‡
Rate per
1,000
patient-
years
Cox proportional
hazard model* GLMM§
Hazard ratio
(95% CI)
Pair-wise
P value
% Decrease per
year (95% CI)
Pair-wise
P value
M vs. N M vs. N
Current albuminuria model Normal (N) 30 28,123 1.1 1 0.0001 1.2% (1.2–1.3) 0.0001
A vs. M A vs. M
Albuminuria category
deﬁned from the AER
value at the time of
estimated GFR
assessment
Microalbuminuria (M) 18 4,041 4.4 3.3 (1.8–6.1) 0.0001 1.8% (1.6–1.9) 0.0001
A vs. N A vs. N
Macroalbuminuria (A) 41 837 46.7 15.3 (8.9–26.3) 0.0001 5.7% (4.5–6.8) 0.0001
M vs. N M vs. N
History of albuminuria model Normal (N) 21 21,069 1.0 1 0.281 1.2% (1.2–1.3) 0.0007
A vs. M A vs. M
Albuminuria category
deﬁned from the highest
AER value observed
before or at the time of
estimated GFR
assessment
Microalbuminuria (M) 14 10,492 1.3 0.7 (0.4–1.4) 0.0001 1.4% (1.3–1.4) 0.0001
A vs. N A vs. N
Macroalbuminuria (A) 54 1,440 36.1 8.6 (5.0–14.7) 0.0001 5.1% (4.0–6.2) 0.0001
Crude risk of developing sustained estimated GFR 60 ml/min/1.73 m
2 (or ESRD) and the relative risk (hazard ratio) estimated from the Cox proportional hazards
model are shown. Mean of the rate of decline (% decrease per year) in estimated GFR was obtained from the general linear mixed model. *Cox proportional hazard
model of the time from DCCT randomization to the initial sustained eGFR 60 ml/min/1.73 m
2 through EDIC year 14, after adjustment for mean arterial pressure
and ACE inhibitor use versus not at each visit as time-dependent covariates. For those with a missing covariate value at a visit, the prior observed value was carried
forward. Mean arterial pressure was computed as (2/3 diastolic blood pressure 
 1/3 systolic blood pressure). ACE inhibitor use was proscribed during DCCT
(1983–1993).†The89patientswitheventsaresubjectswithsustainedeGFR60ml/min/1.73m
2.‡Foreachpatient,patient-yearsiscalculatedastheelapsedwhole
years from randomization into the DCCT to either the visit at which a sustained eGFR 60 ml/min/1.73 m
2 was ﬁrst observed or the last visit at which the eGFR
wasmeasuredifapatienthadnoeventduringthetime.§PercentdecreaseineGFRperyearwhileineachcategoryofalbuminuriaobtainedfromthegeneralizedlinear
mixed model of log-transformed levels of eGFR as a function of time, with heterogeneous random intercept, random slope over time, and residual errors among the
time-dependent AER categories, after adjustment for time-dependent use of ACE inhibitor and time-dependent mean blood pressure at each DCCT-EDIC visit. For
subjects with a missing covariate (AER, ACE inhibitor use, or mean blood pressure) at a visit, the prior observed value was carried forward. For subjects reaching
ESRD, an eGFR value of 15 ml/min/1.73 m
2 was assigned thereafter for annual visits.
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macroalbuminuria. The risk increases
were not as great using a history of mac-
roalbuminuria,inpartbecausemanysub-
jectswhodevelopedmicroalbuminuriaor
macroalbuminuria later reverted to nor-
mal.Thus,transientelevationsofAERdid
not appear to be as strongly associated
with sustained effects on renal function.
Figure 2—A: Estimates of the mean levels of eGFR at each DCCT-EDIC follow-up year among subjects currently with normal AER, or microalbu-
minuria or macroalbuminuria at that time, obtained from the general linear mixed model in Table 2. Subjects may switch from one AER category to
anotherdependingontheircurrentAERlevelsateachvisit.ForeachAERcategory,theestimatedmeanlevelsofeGFRareshownforintervalsduring
whichatleast20subjectshadavisit.B:SmoothedestimatesofthedistributionofpercentchangeineGFRperyearwhilesubjectswereineachcurrent
AER category. The y-axis is the probability density or the derivative of the probability distribution such that the integrated area under each curve
equals1.Eachpatient’srateofchangeineGFRwhilecurrentlyineachAERcategoryisestimatedfromthegenerallinearmixedmodelinTable2(the
currentalbuminuriamodel).NotetherangeofsubstantiallyincreasedratesofdeclineineGFRwhilesubjectshadmacroalbuminuriarelativetothose
while having normal albuminuria or microalbuminuria.
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demonstrate that eGFR levels declined at
an accelerating rate as the AER levels pro-
gressed from normal, to microalbumin-
uriaandtomacroalbuminuria.Therateof
decline in eGFR was signiﬁcantly greater
among individuals with macroalbumin-
uria by history or the current value (5.1,
5.7%) at a visit compared with individu-
als with normal AER (1.2%, 1.2%) or mi-
croalbuminuria (1.4, 1.8%). The rate of
decline for individuals with microalbu-
minuria was closer to, but signiﬁcantly
different from, that of subjects with nor-
mal AER (P  0.001). The 5.7% decline
per year while subjects concurrently had
macroalbuminuria translates into a sub-
stantial44%lossofrenalfunctionover10
years. In some, this rate of decline was in
the range of 10–20% per year, corre-
sponding to 65–89% loss of renal func-
tion over 10 years. A correlation of
progressivedeclineinGFRwithprogress-
ing stages of albuminuria has also been
shown in the Joslin cohort (9).
The pathophysiology and clinical sig-
niﬁcanceofthelowGFRlevelsinpatients
without albuminuria is unclear. In eight
type 1 diabetic patients with normal AER
and decreased GFR, Lane et al. (5) found
that their biopsy results were virtually in-
distinguishablefrompatientswithsimilar
decreases in GFR and elevated urinary
AER. Similar biopsy ﬁndings were re-
ported by Caramori et al. (7) in 23 type 1
diabetic patients with less severe de-
creases of GFR without elevations of uri-
nary AER.
In patients with type 2 diabetes, one
large study (4) showed that subjects with
macroalbuminuria had a greater rate of
fallofeGFRthansubjectswithmicroalbu-
minuriaornormalalbuminexcretion,but
this was not shown in a second smaller
study(19).Athirdstudyofamixedgroup
ofsubjectswithtype1andtype2diabetes
found that subjects without albuminuria
hadalowerriskofworseningofGFRthan
subjects with albuminuria (20).
Undoubtedly,othercausesofchronic
kidney disease must also be present in
some patients with decreased eGFR and
normal AER, and some may just reside in
the lowest part of the normal range of
GFR. However, the limited number of bi-
opsy studies of type 1 diabetic patients
suggests that many have diabetic glo-
merulopathy (5,7). Although some stud-
ies have suggested that the standard
immunoassay for urinary albumin under-
estimates urine albumin levels in the low
range compared with a high pressure liq-
uid chromatography method (21), others
have not found this to be so (22). At
present, immunoassay remains the stan-
dard methodology.
Limitations of our study include the
use of the Modiﬁcation of Diet in Renal
Disease formula to estimate GFR rather
than a direct measurement of GFR, a lack
of kidney biopsies, and the use of a 4-h
insteadofa24-hurinecollectiontoassess
albumin excretion status. None of these
are routine in clinical practice. The 4-h
urine collections for albumin have been
usedintheDCCT/EDICstudysince1983
and have been used previously by the
Steno Study Group (23) and the Pitts-
burgh Epidemiology of Diabetes Compli-
cations Study (24). The Pittsburgh group
also showed that the 4-h collection corre-
lated highly (r  0.942) with the 24-h col-
lection and found a similar correlation with
the albumin/creatinine ratio (0.940) (24).
Our studies have also shown that
there is substantial within-subject varia-
tion in the 4-h estimated AER and in the
excretion rate expressed per 24 h. Over
the 23 years spanned by these data, ad-
justing for temporal trends, the intraclass
correlation among repeated values within
subjects was 0.49, for both the 4-h values
and those extrapolated to 24 h. The intra-
class correlation, however, is substan-
tially higher (0.80) during the later years
oftheEDICstudy(2004–2008)whenthe
levels of AER were higher.
The albumin-to-creatinine ratio,
measured annually during EDIC since
2004, had a lower intraclass correlation
(0.685) than our 4-h AER data (0.803),
and when used as an outcome in compar-
isonsoftheDCCTtreatmentgroups,AER
and ACR show similar results. Thus, we
would expect that longitudinal measures
of ACR would provide similar effects on
longitudinaleGFRasthoseshownherein.
In summary, 24% of the 89 subjects
with sustained eGFR levels 60 ml/min/
1.73 m
2 in the DCCT/EDIC study did not
have a history of microalbuminuria or
macroalbuminuriaonannualvisitsbefore
developing sustained eGFR levels 60
ml/min/1.73 m
2. However, we also show
that the course of renal function in the
DCCT/EDICsubjects,basedoneGFRlev-
els, is substantially worse when mac-
roalbuminuria is present. Our ﬁndings
support the recommendations of Jerums
etal.(25)thatbotheGFRandAERshould
be assessed in the evaluation of kidney
disease in diabetic patients.
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